ArticleMolecular pharmaceutics2026
Route of Administration Determines the Immunosuppressive Mechanism of Bifunctional Peptide Inhibitors in a Mouse EAE Model.
Article in Molecular pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Individuals diagnosed with multiple sclerosis (MS), an autoimmune disease, experience both physical and cognitive impairments due to the degeneration of the myelin sheath surrounding neurons triggered by autoreactive T cells and antibodies. Current MS therapies based on immunosuppressants often result in systemic immune suppression, known as immune tolerance, which leads to side effects including risk of infection and malignancy. Previously, we reported bifunctional peptide inhibitors (BPIs) that can induce antigen-specific immune tolerance and suppress disease progression in a mouse MS model of experimental autoimmune encephalomyelitis (EAE). While BPIs showed similar effectiveness via different routes of administration including intravenous (IV), subcutaneous (SC), and intraperitoneal (IP), whether the route of administration, specifically, mediates immunosuppressive mechanisms used to suppress EAE has not yet been studied. In this study, we prepared BPIs based on the model antigen ovalbumin (OVA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.